Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Total Liabilities for 11 consecutive years, with $188.3 million as the latest value for Q3 2025.

  • Quarterly Total Liabilities rose 23.93% to $188.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $188.3 million through Sep 2025, up 23.93% year-over-year, with the annual reading at $207.3 million for FY2024, 38.16% up from the prior year.
  • Total Liabilities for Q3 2025 was $188.3 million at Editas Medicine, down from $191.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $207.3 million in Q4 2024, with the low at $110.3 million in Q1 2022.
  • Average Total Liabilities over 5 years is $150.3 million, with a median of $145.9 million recorded in 2024.
  • The sharpest move saw Total Liabilities tumbled 38.71% in 2021, then surged 38.16% in 2024.
  • Over 5 years, Total Liabilities stood at $123.8 million in 2021, then increased by 24.06% to $153.6 million in 2022, then fell by 2.33% to $150.1 million in 2023, then soared by 38.16% to $207.3 million in 2024, then decreased by 9.17% to $188.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $188.3 million, $191.4 million, and $201.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.